Integra LifeSciences Holdings (IART) reported a return to profitability in its Q2 2026 earnings, posting sales of $418.76 million and net income of $4.48 million, a stark contrast to a $484.07 million loss in the prior year. The company has adjusted its Q3 revenue guidance to $410-$425 million and lowered its full-year expectations to a range of $1.654-$1.695 billion due to currency impacts. Despite a recent 52% rise in share price, analysts believe the stock is undervalued, suggesting a fair value of $27, reflecting confidence in ongoing operational improvements. However, risks associated with regulatory challenges and pricing pressure remain.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://uk.finance.yahoo.com/news/integra-lifesciences-holdings-iart-returns-031645676.html
